Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Owen ClarkIngo K Mellinghoff

Abstract

IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) and concomitantly produce reduced NADPH from NADP(+) Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its normal enzymatic activity and gains a new ability to produce the "oncometabolite" R(-)-2-hydroxyglutarate (R-2-HG). R-2-HG competitively inhibits α-KG-dependent enzymes which play crucial roles in gene regulation and tissue homeostasis. Expression of mutant IDH impairs cellular differentiation in various cell lineages and promotes tumor development in cooperation with other cancer genes. First-generation inhibitors of mutant IDH have entered clinical trials, and have shown encouraging results in patients with IDH-mutant AML. This article summarizes recent progress in our understanding of the role of mutant IDH in tumorigenesis.Clin Cancer Res; 22(8); 1837-42. ©2016 AACR.

References

Apr 9, 2004·The Biochemical Journal·Younes AchouriEmile Van Schaftingen
Sep 9, 2006·Science·Tobias SjöblomVictor E Velculescu
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Feb 28, 2009·The American Journal of Pathology·Takuya WatanabeHiroko Ohgaki
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Apr 20, 2010·Cancer Cell·Houtan NoushmehrUNKNOWN Cancer Genome Atlas Research Network
Aug 24, 2010·Trends in Biochemical Sciences·Christoph Loenarz, Christopher J Schofield
Feb 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Zachary J ReitmanHai Yan
Apr 5, 2011·EMBO Reports·Rasheduzzaman ChowdhuryAkane Kawamura
Mar 24, 2012·The Journal of Biological Chemistry·Roberta LeonardiCharles O Rock
Aug 14, 2012·Oncotarget·Genglin JinHai Yan
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 26, 2013·Genes & Development·Chao LuCraig B Thompson
Dec 25, 2013·Neuro-oncology·Charles ChesnelongJ Gregory Cairncross
Jan 21, 2014·Cell Stem Cell·Lev M KatsPier Paolo Pandolfi
Feb 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·M Ryan Corces-ZimmermanRavindra Majeti
Jul 6, 2014·Blood·Leonie I KroezeUNKNOWN EORTC Leukemia Group and GIMEMA

❮ Previous
Next ❯

Citations

Aug 21, 2016·Mutation Research. Reviews in Mutation Research·Bani Bandana Ganguly, N N Kadam
Oct 11, 2016·Leukemia·B C MedeirosR Swords
Nov 15, 2016·Oncogene·V TakiarL W T Cheung
Feb 7, 2017·Expert Review of Gastroenterology & Hepatology·Douglas V N P OliveiraJesper B Andersen
Jul 15, 2017·Antioxidants & Redox Signaling·Lauren R Bringman-RodenbargerDavid B Lombard
Mar 16, 2018·Future Oncology·Guillermo Montalban-Bravo, Courtney D DiNardo
Apr 12, 2018·Critical Reviews in Biochemistry and Molecular Biology·Surinder Kumar, David B Lombard
Feb 18, 2018·Journal of Neuro-oncology·David S HershJeffrey A Winkles
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J van den BentSusan M Chang
Apr 24, 2018·The American Journal of Surgical Pathology·Jeffrey K MitoVickie Y Jo
May 18, 2018·Expert Review of Clinical Pharmacology·James Dugan, Daniel Pollyea
Aug 14, 2018·Current Opinion in Oncology·Mirco FriedrichMichael Platten
Jan 9, 2019·Antioxidants & Redox Signaling·Sergey I Dikalov, Anna E Dikalova
Jul 11, 2019·Cancers·Vinee PurohitCostas A Lyssiotis
Oct 9, 2019·Current Opinion in Neurology·Jason M BecktaAnthony J Chalmers
Aug 14, 2019·Journal of Molecular Cell Biology·Lichao LiuXiaohua Shen
Oct 26, 2018·Blood Advances·Alex Aleshin, Peter L Greenberg
Dec 10, 2019·Leukemia & Lymphoma·Namrata S ChandhokThomas Prebet
Mar 19, 2020·American Society of Clinical Oncology Educational Book·Martin J van den BentRanjit S Bindra
Mar 1, 2020·Biomolecules·Alvinsyah Adhityo PramonoJoseph R Bertino
Apr 21, 2020·Expert Review of Hematology·Xavier ThomasMaël Heiblig
May 29, 2020·The British Journal of Radiology·Martin Kery, Ioanna Papandreou
May 12, 2018·International Journal of Molecular Medicine·Igor BryukhovetskiyYuri Khotimchenko
Feb 15, 2020·International Journal of Molecular Sciences·Dylan MordauntMaria Fuller
Oct 25, 2016·Nature Reviews. Cancer·Lucas B SullivanMatthew G Vander Heiden
Apr 3, 2019·Brain Tumor Pathology·Kosuke Aoki, Atsushi Natsume
Oct 24, 2017·Nature Communications·Georg Karpel-MasslerMarkus D Siegelin
Feb 3, 2019·Cells·Charlotte DomblidesBenjamin Faustin
Jun 6, 2019·Frontiers in Oncology·Danielle GolubDimitris G Placantonakis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.